NCT00854620View on ClinicalTrials.gov

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

January 31, 2011

Conditions
Carcinoma, Renal CellKidney DiseaseKidney Cancer
Interventions
DRUG

Sorafenib

Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00854620 - Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | Biotech Hunter | Biotech Hunter